酮替芬治疗支气管哮喘的长期试验
Long term trial of ketotifen in bronchial asthma.
作者信息
Podleski W K, Zelenak T M, Schmidt J L
出版信息
Ann Allergy. 1984 Jun;52(6):406-10.
PMID:6428279
Abstract
Ketotifen in a dose of 1 mg p.o. q 12 h was compared with placebo in a double-blind, twelve month parallel group trial in 17 randomly selected patients with bronchial asthma. Among 13 patients treated with ketotifen, nine have been classified as responders and four as non-responders. Responders were young and teenaged individuals, athletically oriented, with moderate asthma. It is our impression that ketotifen offers a new therapeutic dimension in the prophylaxis of bronchial asthma.
摘要
在一项针对17名随机选取的支气管哮喘患者的双盲、为期12个月的平行组试验中，将剂量为1毫克口服、每12小时一次的酮替芬与安慰剂进行了比较。在13名接受酮替芬治疗的患者中，9名被归类为有反应者，4名被归类为无反应者。有反应者为年轻人和青少年，以运动为导向，患有中度哮喘。我们的印象是，酮替芬在支气管哮喘的预防方面提供了一个新的治疗维度。
Zotero 插件